-+ 0.00%
-+ 0.00%
-+ 0.00%

NewGenIvf Plans to Use Offering Proceeds to Expand Nodexus Cytometry Technology

PUBT·11/20/2026 14:46:04
NewGenIvf Plans to Use Offering Proceeds to Expand Nodexus Cytometry Technology
  • NewGenIvf plans to fund commercialization and expansion of Nodexus advanced cytometry technology and its assisted reproductive services platform.
  • Funding will come from net proceeds of an approximately $2.5 million offering, together with existing cash.
  • Other planned uses include strategic investments in prediction-market and digital-asset/AI initiatives, UAE real estate interests and general corporate purposes.
  • Approximately $625,000 of gross proceeds will fund the repurchase of $584,112 in principal amount of the Exchange Note.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewGenIvf Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611200943PRIMZONEFULLFEED9882113) on November 20, 2026, and is solely responsible for the information contained therein.